Advertisement
U.S. markets closed

Senti Biosciences, Inc. (SNTI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4101-0.0084 (-2.01%)
At close: 03:59PM EST
0.4075 -0.00 (-0.63%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.4185
Open0.4099
Bid0.4075 x 1000
Ask0.4118 x 1100
Day's Range0.4051 - 0.4184
52 Week Range0.2700 - 1.5900
Volume41,321
Avg. Volume766,255
Market Cap18.268M
Beta (5Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)-1.9600
Earnings DateMar 04, 2024 - Mar 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SNTI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Senti Biosciences, Inc.
    Daily – Vickers Top Insider Picks for 03/13/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • GlobeNewswire

    Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

    – Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% reduction in workforce, expected to extend cash runway into 1Q 2025 – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology

  • Zacks

    Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

    The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

  • Benzinga

    Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

    Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells. The company plans to initiate a Phase 1 clinical trial of SENTI-202 in 2024 in multiple sites in the U.S. and Australia and expects to tr